Page last updated: 2024-11-05

tranexamic acid and Heart Defects, Congenital

tranexamic acid has been researched along with Heart Defects, Congenital in 20 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.

Research Excerpts

ExcerptRelevanceReference
"Tranexamic acid has been used both topically and systemically and plays a vital role in pediatric cardiac surgery by reducing blood loss and blood product requirement."2.84Topical and low-dose intravenous tranexamic acid in cyanotic cardiac surgery. ( Deodhar, S; Gandhi, H; Pandya, H; Patel, H; Patel, J; Prajapati, M, 2017)
" There is a reasonable body of literature examining antifibrinolytic therapy in congenital heart surgery, but the large variability in patients studied, procedures, methods, and dosing schemes makes a quantitative analysis of this literature impractical."2.44Antifibrinolytic therapy in surgery for congenital heart disease. ( Eaton, MP, 2008)
"Spinal surgery for scoliosis has been performed in selected patients with single ventricle physiology at a single institution without mortality for 25 years."1.62Surgical Correction of Scoliosis in Children with Severe Congenital Heart Disease and Palliated Single Ventricle Physiology. ( Cohen, LL; Emans, JB; Hedequist, DJ; Marshall, AC; Przybylski, R, 2021)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (10.00)18.2507
2000's7 (35.00)29.6817
2010's10 (50.00)24.3611
2020's1 (5.00)2.80

Authors

AuthorsStudies
Cohen, LL1
Przybylski, R1
Marshall, AC1
Emans, JB1
Hedequist, DJ1
Junejo, F1
Akhtar, MI1
Hamid, M1
Ahmed, SS1
Minai, F1
Amanullah, M1
Faraoni, D2
Rozen, L2
Willems, A2
Torres, CS1
Pereira, LM1
Demulder, A2
Van der Linden, P2
Sanchez Torres, C1
Noubouossie, DC1
Barglazan, D1
Patel, J1
Prajapati, M1
Patel, H1
Gandhi, H1
Deodhar, S1
Pandya, H1
Breuer, T1
Martin, K3
Wilhelm, M1
Wiesner, G3
Schreiber, C3
Hess, J1
Lange, R1
Tassani, P3
Schindler, E1
Photiadis, J1
Sinzobahamvya, N1
Döres, A1
Asfour, B1
Hraska, V1
Gertler, R1
Sterner, A1
MacGuill, M1
Hörer, J1
Vogt, M1
Graham, EM1
Atz, AM1
Gillis, J1
Desantis, SM1
Haney, AL1
Deardorff, RL1
Uber, WE1
Reeves, ST1
McGowan, FX1
Bradley, SM1
Spinale, FG1
Pasquali, SK1
Li, JS1
He, X1
Jacobs, ML1
O'Brien, SM1
Hall, M1
Jaquiss, RD1
Welke, KF1
Peterson, ED1
Shah, SS1
Jacobs, JP1
Giordano, R1
Palma, G1
Poli, V1
Palumbo, S1
Russolillo, V1
Cioffi, S1
Mucerino, M1
Mannacio, VA1
Vosa, C1
Vacharaksa, K1
Prakanrattana, U1
Suksompong, S1
Chumpathong, S1
Chauhan, S2
Das, SN1
Bisoi, A2
Kale, S2
Kiran, U2
Kumar, N1
Mittal, D1
Venugopal, P1
Varela Crespo, CA1
Sanabria Carretero, P1
Palomero Rodríguez, MA1
Tormo las de Heras, C1
Rodríguez Pérez, E1
Goldman Tarlousky, L1
Eaton, MP1
Reid, RW1
Zimmerman, AA1
Laussen, PC1
Mayer, JE1
Gorlin, JB1
Burrows, FA1
Williams, GD1
Ramamoorthy, C1
Levin, E1
Wu, J1
Devine, DV1
Alexander, J1
Reichart, C1
Sett, S1
Seear, M1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery: a Multicenter Randomized Double Blind Placebo Controlled Therapeutic and Pharmaco-biological Dose Ranging Study (TRACES) for Its Optimal Benefit/Risk[NCT02797119]Phase 4225 participants (Actual)Interventional2016-03-15Terminated (stopped due to Study will be stopped due to the impossibility of reaching the objective of inclusions within a reasonable time frame and taking into account the recommendations of the international WOMAN study)
Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis Using an in Vitro Experimental Model of Fibrinolysis.[NCT02352675]40 participants (Actual)Observational2015-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for tranexamic acid and Heart Defects, Congenital

ArticleYear
Antifibrinolytic therapy in surgery for congenital heart disease.
    Anesthesia and analgesia, 2008, Volume: 106, Issue:4

    Topics: Antifibrinolytic Agents; Aprotinin; Child; Heart Defects, Congenital; Humans; Infant, Newborn; Place

2008

Trials

9 trials available for tranexamic acid and Heart Defects, Congenital

ArticleYear
Comparison between Intravenous Boluses versus Infusion of Tranexamic Acid (TXA) to Reduce Bleeding in Paediatric Cyanotic Congenital Heart Disease (CHD) Surgeries.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2018, Volume: 28, Issue:3

    Topics: Administration, Intravenous; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cardi

2018
Topical and low-dose intravenous tranexamic acid in cyanotic cardiac surgery.
    Asian cardiovascular & thoracic annals, 2017, Volume: 25, Issue:2

    Topics: Administration, Intravenous; Administration, Topical; Adolescent; Antifibrinolytic Agents; Blood Coa

2017
The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2009, Volume: 35, Issue:1

    Topics: Antifibrinolytic Agents; Aprotinin; Blood Component Transfusion; Blood Loss, Surgical; Drug Administ

2009
Tranexamic acid as a means of reducing the need for blood and blood component therapy in children undergoing open heart surgery for congenital cyanotic heart disease.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2002, Volume: 85 Suppl 3

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiopulmonary Bypass; Child; Chi

2002
Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery.
    Journal of cardiothoracic and vascular anesthesia, 2004, Volume: 18, Issue:2

    Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation Tests; Blood Transfusion;

2004
Dose comparison of tranexamic acid in pediatric cardiac surgery.
    Asian cardiovascular & thoracic annals, 2004, Volume: 12, Issue:2

    Topics: Adolescent; Antifibrinolytic Agents; Biomarkers; Blood Coagulation; Cardiac Surgical Procedures; Car

2004
[Effect of tranexamic acid on postoperative bleeding in pediatric heart surgery].
    Revista espanola de anestesiologia y reanimacion, 2007, Volume: 54, Issue:3

    Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Blood Proteins; Cardiac Surgical Procedur

2007
The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:5

    Topics: Antifibrinolytic Agents; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgica

1997
Hemostatic parameters and platelet activation marker expression in cyanotic and acyanotic pediatric patients undergoing cardiac surgery in the presence of tranexamic acid.
    Thrombosis and haemostasis, 2000, Volume: 83, Issue:1

    Topics: Antifibrinolytic Agents; Child; Child, Preschool; Coronary Artery Bypass; Cyanosis; Female; Heart De

2000

Other Studies

10 other studies available for tranexamic acid and Heart Defects, Congenital

ArticleYear
Surgical Correction of Scoliosis in Children with Severe Congenital Heart Disease and Palliated Single Ventricle Physiology.
    Spine, 2021, Jul-15, Volume: 46, Issue:14

    Topics: Adolescent; Adult; Child; Cohort Studies; Female; Heart Defects, Congenital; Heart Ventricles; Human

2021
Experimental model of hyperfibrinolysis designed for rotational thromboelastometry in children with congenital heart disease.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2015, Volume: 26, Issue:3

    Topics: Antifibrinolytic Agents; Child; Child, Preschool; Fibrinolysis; Heart Defects, Congenital; Hemorrhag

2015
Effective tranexamic acid concentration for 95% inhibition of tissue-type plasminogen activator induced hyperfibrinolysis in children with congenital heart disease: A prospective, controlled, in-vitro study.
    European journal of anaesthesiology, 2015, Volume: 32, Issue:12

    Topics: Adult; Antifibrinolytic Agents; Child; Child, Preschool; Female; Fibrinolysis; Heart Defects, Congen

2015
Tranexamic acid: an alternative to aprotinin as antifibrinolytic therapy in pediatric congenital heart surgery.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2011, Volume: 39, Issue:4

    Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Proced

2011
Comparison of blood-sparing efficacy of ε-aminocaproic acid and tranexamic acid in newborns undergoing cardiac surgery.
    The Thoracic and cardiovascular surgeon, 2011, Volume: 59, Issue:5

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgica

2011
Is tranexamic acid really an alternative to aprotinin?
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2012, Volume: 41, Issue:2

    Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Female; Heart

2012
Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery.
    The Journal of thoracic and cardiovascular surgery, 2012, Volume: 143, Issue:5

    Topics: Age Factors; Analysis of Variance; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac

2012
Comparative analysis of antifibrinolytic medications in pediatric heart surgery.
    The Journal of thoracic and cardiovascular surgery, 2012, Volume: 143, Issue:3

    Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Chi-Square Distribu

2012
Tranexamic acid therapy in pediatric cardiac surgery: a single-center study.
    The Annals of thoracic surgery, 2012, Volume: 94, Issue:4

    Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Child, Preschool; Dose

2012
Con: the routine use of aprotinin during pediatric cardiac surgery is not a benefit.
    Journal of cardiothoracic and vascular anesthesia, 1999, Volume: 13, Issue:6

    Topics: Adult; Anti-Inflammatory Agents; Aprotinin; Blood Transfusion; Cardiac Surgical Procedures; Child; C

1999